Contains 0.75% metronidazole, which is an established antibacterial agent. It is effective against a variety of organisms including anaerobic bacteria.

Cream with 3.75% imiquimod, is an immune response modifier that is the lead compound of the imidazoline family.

Cream containing 5% imiquimod, an immune response modifier that is effective against viral infections and acts as an anti-tumour agent, principally by induction of alpha interferon and other cytokines.

Dermatix is available as a silicone topical gel

Cream with pimecrolimus, a lipophilic anti-inflammatory ascomycin macrolactam derivative and a cell selective inhibitor of the production and release of pro-inflammatory cytokines. Its skin-selective pharmacological profile is different to that of corticosteroids.

Topical cytostatic cream preparation with 5% fluorouracil that exerts a beneficial therapeutic effect on neoplastic and pre-neoplastic skin lesions without damaging normal skin. The pattern of response follows this sequence: erythema, vesiculation, erosion, ulceration, necrosis and epithelialisation. Formerly Efudix.

Gel combination therapy of clindamycin and tretinoin. Clindamycin is a semisynthetic derivative of the parent compound lincomycin that is produced by Streptomyces lincolnensis and is predominantly bacteriostatic. Topical tretinoin has both comedolytic and anti-inflammatory effects. Tretinoin decreases cohesiveness of follicular epithelial cells resulting in decreased microcomedone formation. Additionally, tretinoin stimulates mitotic activity and increased turnover of follicular epithelial cells, causing extrusion of the comedones.

Minocin MR capsules contain the active ingredient minocycline as minocycline hydrochloride, which is a semi-synthetic derivative of tetracycline

Elasticated viscose stockinette.

An emollient white soft paraffin-based cream.